Category: Biotech
-
Anatomy of the “synbio winter” — the tools/DNA-synthesis model survived, the platform/biomanufacturing model foundered, and whether the winter was a science failure or a business-model failure
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All revenues, margins, valuations, layoff rates and bankruptcy facts are attributed to each company’s own reporting (SEC 8-K/10-Q, corporate press releases) or the trade press; company claims, institutional statistics and market estimates are…
-
Biofoundries and the DBTL cycle — automation and AI industrialize the design-build-test-learn loop, but do they close the “design-predictability gap” or just industrialize trial-and-error?
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. Every fold-improvement, titer and throughput figure is attributed to the specific campaign, strain, condition and source; peer-reviewed results, company self-report and marketing are labeled separately (noted inline). Descriptions of listed and defunct companies…
-
Genetic circuits and chassis engineering — where “engineering biology” meets biological reality: Cello’s 92% is a real but bounded demonstration, and the true bottleneck is design predictability, not parts availability
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All circuit-accuracy, gene-count, metabolic-burden and generation-count figures are attributed to the specific paper, strain, library and condition in which they were measured; peer-reviewed results are separated from review or secondary…
-
DNA synthesis and genome writing — column chemistry is already cheap and mature; the bottleneck is not the cost of writing DNA, it has moved downstream to design, assembly and context
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All cost, error-rate, length and yield figures are attributed to the platform, kit or publication that reported them; company list prices and vendor performance specs are separated from peer-reviewed and technical-literature values (noted…
-
In-vivo gene editing — big pharma bet on the delivery platform, not the editor, and the real bottleneck (hard outcomes) is untouched
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In 2025–26 big pharma bought its way into in-vivo gene editing and in-vivo CAR-T (Eli Lilly–Verve up to $1.3B; AbbVie–Capstan up to $2.1B). But the bet…
-
The real clinical cost of in-vivo gene editing is not potency but irreversibility — reading the MAGNITUDE hepatotoxicity signal, the death, and asymmetric risk by evidence tier
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Across Parts 0–3 this series showed that in-vivo editing has already matched siRNA/ASO on the headline metric — knockdown depth (PCSK9 −88%, TTR −87%, Z-AAT…
-
In-vivo gene editing, Part 2 — delivery is the rate-limiting step, and why that confines the field to the liver
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. Delivery-performance figures (editing efficiency, knockdown) are largely company, conference or preclinical (NHP/mouse) data and are attributed as such in the text; safety events are attributed to regulatory/source documents and unresolved…
-
Editing modality — nuclease, base, prime — and why the most precise editor is the least clinically mature
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In-vivo gene editing is not one technology but a precision spectrum: nuclease (double-strand break, random indels — a “knockout” tool) → base editing (single-base substitution, no…
Uthando Nethemba 